Summary
The FDA on Tuesday signed off on Supernus Pharmaceuticals apomorphine hydrochloride injectionto be marketed under the brand name Onapgofor use in adults with Parkinsons disease.
Source: BioSpace
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
